Small Molecules Binding TDP-43 to Block Nucleic Acid Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration of the TDP-43 type (FTLD-TDP-43), chronic traumatic encephalopathy (CTE), and inclusion body myositis (IBM) lack disease-modifying therapies that can slow or halt disease progression, improve quality of life, and extend lifespan, as they primarily focus on symptomatic relief.
Innovation Solution
Development of compounds that bind to the TDP-43 protein, specifically small molecules capable of modulating TDP-43, including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, isotopic analogs, and prodrugs, to prevent or treat diseases associated with TDP-43 proteinopathies by blocking nucleic acid binding to TDP-43.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic treatments are used for ALS and TDP-43 related diseases, then quality of life and lifespan are improved, but disease progression is not slowed or halted
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that bind to TDP-43 protein and block its interaction with nucleic acids. These compounds serve as mediators between the disease pathology and therapeutic intervention, preventing harmful TDP-43 nucleic acid binding while maintaining essential functions. The compounds act as molecular intermediaries that modulate protein-nucleic acid interactions to achieve disease-modifying effects.
2Productivity
If disease-modifying therapies are developed to slow or halt disease progression, then unmet medical need is addressed, but current treatments lack such capability
Solution Approach 1:
The patent employs parameter changes by modifying the binding characteristics of TDP-43 through small molecule intervention. The compounds alter the biochemical parameters of TDP-43 nucleic acid binding, changing the affinity and specificity of these interactions. By changing the binding parameters rather than eliminating TDP-43 function entirely, the therapy achieves disease modification while preserving essential physiological roles of TDP-43.
3Reliability
If small molecules binding to TDP-43 are developed, then nucleic acid binding is blocked and disease progression is slowed, but no FDA-approved disease-modifying treatments currently exist
Solution Approach 1:
The patent enables TDP-43 to serve itself by designing compounds that modulate rather than eliminate its function. The small molecules allow TDP-43 to maintain its essential cellular roles while preventing pathological nucleic acid binding. This self-service approach preserves the protein's beneficial functions while correcting its harmful interactions, potentially facilitating regulatory approval by maintaining physiological balance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed compounds effectively treat or prevent TDP-43-related diseases by modulating TDP-43, potentially slowing disease progression and improving quality of life for patients, and can also be used as imaging agents for diagnostic purposes.
Implementation Method 1
compounds that bind to the protein trans-activating response (TAR) DNA binding protein TDP-43 and block the binding of nucleic acid to TDP-43
Data Source
AI summary
The present invention relates to compounds that bind to TDP-43 and may have a therapeutic effect in treating a human disease, such as amyotrophic lateral sclerosis, frontotemporal lobar degeneration, hippocampal sclerosis of aging, chronic traumatic encephalopathy, inclusion body myositis, Alzheimer's disease, and/or Alzheimer's disease related disorders.